Literature DB >> 18376796

CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast.

Lai Meng Looi1, Phaik Leng Cheah, Wenran Zhao, Min-Hwei Ng, Cheng Har Yip.   

Abstract

Metastasising ability connotes one of the most important life-threatening properties of malignant neoplasms. Recent studies indicate that CD44 proteins, multifunctional cell adhesion molecules which contribute to "homing" of lymphocytes to lymph nodes as well as cell-cell and cell-matrix interactions, are potential markers of tumour progression. However, whether CD44 expression by human tumours contribute to increased metastatic risk remains controversial. In an attempt to clarify its role in breast cancer, we have investigated the correlation between CD44 expression by breast carcinoma and the presence of axillary lymph node metastases. CD44 expression was detected using a standard immunoperoxidase method on formalin-fixed, paraffin-embedded, primary infiltrating ductal breast carcinoma tissues taken from 60 female patients who underwent mastectomy with axillary node clearance. Tumours were graded according to the modified Bloom and Richardson criteria. 62% of patients had histologically-proven lymph node metastasis. 40% of primary cancers exhibited cytoplasmic membrane immunopositivity for CD44. 46% of primary tumours which have metastasied to axillary lymph nodes were CD44 positive whereas 30% of tumours which have not metastasised expressed CD44. CD44 positivity was expressed by 20% of grade 1, 31% grade 2 and 58% grade 3 tumours. Our results suggest that CD44 may have a role in the progression of breast cancer and emphasise the need to investigate its interaction with other mechanisms of cancer advancement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18376796

Source DB:  PubMed          Journal:  Malays J Pathol        ISSN: 0126-8635            Impact factor:   0.656


  8 in total

1.  In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.

Authors:  Veronique Neumeister; Seema Agarwal; Jennifer Bordeaux; Robert L Camp; David L Rimm
Journal:  Am J Pathol       Date:  2010-03-12       Impact factor: 4.307

2.  Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer.

Authors:  Min Hye Jang; Hyun Jong Kang; Ki Seok Jang; Seung Sam Paik; Wan Seop Kim
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

3.  CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours.

Authors:  Zahra Madjd; Ali Zare Mehrjerdi; Ali Mohammad Sharifi; Saadat Molanaei; Shahriar Zohourian Shahzadi; Mohsen Asadi-Lari
Journal:  Cancer Immun       Date:  2009-04-23

4.  Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.

Authors:  Hanxiao Xu; Yijun Tian; Xun Yuan; Yu Liu; Hua Wu; Qian Liu; Gen Sheng Wu; Kongming Wu
Journal:  Onco Targets Ther       Date:  2016-01-21       Impact factor: 4.147

5.  Effect of CD44st and HER2 expression on the postoperative prognosis of breast cancer patients.

Authors:  Dan Dan Chen; Jun An Ji; Hai Cui Yan; Guan Hong Huang; Xin Jian Fang
Journal:  Onco Targets Ther       Date:  2019-01-15       Impact factor: 4.147

6.  CD44 Variant Exon 6 Isoform Expression as a Potential Predictor of Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type.

Authors:  Primariadewi Rustamadji; Elvan Wiyarta; Kristina A Bethania
Journal:  Int J Breast Cancer       Date:  2021-12-10

7.  Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6.

Authors:  Fahe Ji; Dongchu Ma; Zhaozhe Liu; Xiaodong Xie
Journal:  Oncol Lett       Date:  2014-01-24       Impact factor: 2.967

8.  Predictive Value of CD44 for Prognosis in Patients with Breast Cancer.

Authors:  Yousef Roosta; Zohreh Sanaat; Ali Reza Nikanfar; Roya Dolatkhah; Ashraf Fakhrjou
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.